This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joseph Emmerich, MD; Bernard Jacotot, MD
Hôpital Henri Mondor Créteil, France

JAMA. 1989;261(4):554.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor. —

We read with interest the complementary results of the Helsinki Heart Study,^1,2 which concluded that both elevating high-density lipoprotein (HDL) cholesterol levels and lowering low-density lipoprotein cholesterol levels are effective in the primary prevention of coronary heart disease (CHD). Nevertheless, we would point out some questions suggested by a careful analysis of the text.

There was a significant overall difference in the incidence of CHD between the treatment groups among the Fredrickson types (P<.02). The treatment had a statistically significant effect in type IIB, with 19 cardiac end points (33%) in the gemfibrozil group vs 33 (55%) for the placebo one. Are the results also significant for type IIA, with, respectively, 33 events (28%) vs 44 (35%), and for type IV, with four events (21%) vs seven (34%)? The reduction of CHD with gemfibrozil in type IIA appeared to be smaller compared with type . . . [Full Text PDF of this Article]

Footnotes
Edited by Drummond Rennie, MD, Deputy Editor (West); Sharon Iverson, Assistant Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?